Clearance of the New Drug Application for ART25.12 allows Artelo to begin a Phase I study for the drug in chemotherapy-induced peripheral neuropathy.
FDA Clears Artelo Biosciences’ Investigational New Drug Application for Chemotherapy-Induced Peripheral Neuropathy Treatment